Luna Kimihira1, Chifumi Iseki1, Yoshimi Takahashi1, Hidenori Sato1, Hajime Kato1, Hiroaki Kazui2, Nagato Kuriyama3, Madoka Nakajima4, Masakazu Miyajima4, Katsuhiro Endo5, Yoshio Kobayashi6, Takashi Saegusa7, Yasuaki Takeda8, Shunsuke Sato9, Yusuke Tomogane10, Toru Baba11, Hiroji Miyake12, Mitsunori Matsumae13, Satoshi Onozuka14, Hisayuki Murai15, Yoshinaga Kajimoto16, Teruo Kimura17, Masahito Kobayashi18, Masashi Yamazaki19, Hajime Arai4, Takeo Kato20. 1. Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Yamagata, Japan. 2. Department of Psychiatry, Kochi Medical School, Kochi University, Kochi, Japan. 3. Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan. 4. Department of Neurosurgery, Juntendo University School of Medicine, Tokyo, Japan. 5. Department of Neurosurgery, Masu Memorial Hospital, Fukushima, Japan. 6. Department of Geriatric Medicine, Kyorin University School of Medicine, Tokyo, Japan. 7. Department of Neurosurgery, Chiba Rosai Hospital, Chiba, Japan. 8. Department of Neurosurgery, Japan Community Healthcare Organization Tokyo Yamate Medical Center, Tokyo, Japan. 9. Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan. 10. Department of Neurosurgery, Hyogo College of Medicine Hospital, Hyogo, Japan. 11. Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Miyagi, Japan. 12. Department of Neurosurgery, Nishinomiya Kyoritsu Neurosurgical Hospital, Hyogo, Japan. 13. Department of Neurosurgery, Tokai University School of Medicine, Kanagawa, Japan. 14. Department of Neurosurgery, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan. 15. Department of Neurosurgery, Chiba University Hospital, Chiba, Japan. 16. Department of Neurosurgery, Osaka Medical College Hospital, Osaka, Japan. 17. Department of Neurosurgery, Doutou Neurosurgical Hospital, Hokkaido, Japan. 18. Department of Neurosurgery, Saitama Medical University Hospital, Saitama, Japan. 19. Department of Neurology, Hokushin General Hospital Nagano Prefectural Federation of Agricultural Cooperatives for Health and Welfare, Nagano, Japan. 20. Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Yamagata, Japan. Electronic address: tkato@med.id.yamagata-u.ac.jp.
Abstract
INTRODUCTION: Our previous community-based study demonstrated that some individuals with AVIM [asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus (iNPH) on magnetic resonance imaging (MRI)] progressed to iNPH in several years. In this hospital-based study, we investigated the progression rate from AVIM to iNPH and its possible predictors. METHODS: We conducted a prospective study of participants with AVIM from several medical institutions/hospitals in Japan. AVIM is defined as "asymptomatic ventriculomegaly with features of iNPH on MRI"; in the present study, asymptomatic was defined as "0 (no symptoms) or 1 (presence of only subjective, but not objective, symptoms) on the iNPH Grading Scale (iNPH-GS)." We also measured possible predicting factors for AVIM-to-iNPH progression, including age, sex, body weight, blood pressure, diabetes mellitus, dyslipidemia, history of mental disease/head injury/sinusitis/smoking/alcohol-intake, Evans index, and the presence of DESH (disproportionately enlarged subarachnoid-space hydrocephalus) findings on brain MRI, and analyzed these potential predictive values. RESULTS: In 2012, 93 participants with AVIM were registered and enrolled in the study. Of these, 52 participants were able to be tracked for three years (until 2015). Of the 52 participants, 27 (52%) developed iNPH during the follow-up period (11 definite, 6 probable, and 10 possible iNPH), whereas 25 participants remained asymptomatic in 2015. Among the possible predictive factors examined, the baseline scores of iNPH-GS predicted the AVIM-to-iNPH progression. CONCLUSIONS: The multicenter prospective study demonstrated that the progression rate from AVIM to iNPH was ~17% per year, and the baseline scores of iNPH-GS predicted the AVIM-to-iNPH progression.
INTRODUCTION: Our previous community-based study demonstrated that some individuals with AVIM [asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus (iNPH) on magnetic resonance imaging (MRI)] progressed to iNPH in several years. In this hospital-based study, we investigated the progression rate from AVIM to iNPH and its possible predictors. METHODS: We conducted a prospective study of participants with AVIM from several medical institutions/hospitals in Japan. AVIM is defined as "asymptomatic ventriculomegaly with features of iNPH on MRI"; in the present study, asymptomatic was defined as "0 (no symptoms) or 1 (presence of only subjective, but not objective, symptoms) on the iNPH Grading Scale (iNPH-GS)." We also measured possible predicting factors for AVIM-to-iNPH progression, including age, sex, body weight, blood pressure, diabetes mellitus, dyslipidemia, history of mental disease/head injury/sinusitis/smoking/alcohol-intake, Evans index, and the presence of DESH (disproportionately enlarged subarachnoid-space hydrocephalus) findings on brain MRI, and analyzed these potential predictive values. RESULTS: In 2012, 93 participants with AVIM were registered and enrolled in the study. Of these, 52 participants were able to be tracked for three years (until 2015). Of the 52 participants, 27 (52%) developed iNPH during the follow-up period (11 definite, 6 probable, and 10 possible iNPH), whereas 25 participants remained asymptomatic in 2015. Among the possible predictive factors examined, the baseline scores of iNPH-GS predicted the AVIM-to-iNPH progression. CONCLUSIONS: The multicenter prospective study demonstrated that the progression rate from AVIM to iNPH was ~17% per year, and the baseline scores of iNPH-GS predicted the AVIM-to-iNPH progression.
Authors: J F Carlsen; A D L Backlund; C A Mardal; S Taudorf; A V Holst; T N Munch; A E Hansen; S G Hasselbalch Journal: AJNR Am J Neuroradiol Date: 2021-12-30 Impact factor: 3.825
Authors: Jonathan Frederik Carlsen; Tina Nørgaard Munch; Adam Espe Hansen; Steen Gregers Hasselbalch; Alexander Malcolm Rykkje Journal: Neuroradiology Date: 2022-07-24 Impact factor: 2.995